A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALN-CIDEB IN ADULTS WITH FIBROTIC METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
- Registry ID
- ALN-CIDEB-MASH-2603
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- REGENERON PHARMACEUTICALS INC
- Last update
- 2026-07-14
Conditions
- METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Related clinical trials
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF EFIMOSFERMIN ALFA IN PARTICIPANTS WITH KNOWN OR SUSPECTED F2- OR F3-STAGE METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) (ZENITH-2)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF EFIMOSFERMIN ALFA IN PARTICIPANTS WITH BIOPSY-CONFIRMED F2- OR F3-STAGE METABOLIC DYSFUNCTION-ASSOCIATED BOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) (ZENITH-1)
- A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGOZAFERMIN IN SUBJECTS
WITH COMPENSATED CIRRHOSIS DUE TO METABOLIC DYSFUNCTION-ASSOCIATED
STEATOHEPATITIS (MASH)
- A PHASE 2A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE
THE EFFICACY AND SAFETY OF EFINOPEGDUTIDE (MK-6024) IN ADULTS WITH
COMPENSATED CIRRHOSIS SECONDARY TO METABOLIC DYSFUNCTION-ASSOCIATED
STEATOHEPATITIS
- A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGOZAFERMIN IN SUBJECTS
WITH METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH) AND FIBROSIS
View on source registry